Allogeneic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia: An Overview of Obstacles and Opportunities

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2023 Jan 23

PMID 36686358

Authors

Yong-Feng Chen

Jing Li

Ling-Long Xu

Mihnea-Alexandru Gaman

Zhen-You Zou

Affiliations

Soon will be listed here.

Abstract

As an important treatment for acute myeloid leukemia, allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays an important role in reducing relapse and improving long-term survival. With rapid advancements in basic research in molecular biology and immunology and with deepening understanding of the biological characteristics of hematopoietic stem cells, allo-HSCT has been widely applied in clinical practice. During allo-HSCT, preconditioning, the donor, and the source of stem cells can be tailored to the patient's conditions, greatly broadening the indications for HSCT, with clear survival benefits. However, the risks associated with allo-HSCT remain high, hematopoietic reconstitution failure, delayed immune reconstitution, graft-versus-host disease, and post-transplant relapse, which are bottlenecks for further improvements in allo-HSCT efficacy and have become hot topics in the field of HSCT. Other bottlenecks recognized in the current treatment of individuals diagnosed with acute myeloid leukemia and subjected to allo-HSCT include the selection of the most appropriate conditioning regimen and post-transplantation management. In this paper, we reviewed the progress of relevant research regarding these aspects.

Citing Articles

Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives.

Khosroabadi Z, Azaryar S, Dianat-Moghadam H, Amoozgar Z, Sharifi M Mol Med. 2025; 31(1):33.

PMID: 39885388 PMC: 11783831. DOI: 10.1186/s10020-025-01085-w.

Stem cell status and prognostic applications of cuproptosis-associated lncRNAs in acute myeloid leukemia.

Chai Z, Yuan Z, Chen Y Front Cell Dev Biol. 2025; 12:1549294.

PMID: 39877157 PMC: 11772438. DOI: 10.3389/fcell.2024.1549294.

Adoptive NK cell therapy in AML: progress and challenges.

Rady M, Mostafa M, Dida G, Sabet F, Abou-Aisha K, Watzl C Clin Exp Med. 2025; 25(1):41.

PMID: 39820676 PMC: 11748472. DOI: 10.1007/s10238-025-01559-5.

Global landscape of vancomycin-resistant enterococci in hematopoietic stem-cell transplantation patients: a systematic review and meta-analysis.

Nabavi S, Chamanara M, Moghaddam A, Ghorbani M, Heidari R, Khomartash M BMC Infect Dis. 2024; 24(1):1191.

PMID: 39438823 PMC: 11515653. DOI: 10.1186/s12879-024-10100-0.

Advancements and challenges in stem cell transplantation for regenerative medicine.

Wei L, Yan W, Shah W, Zhang Z, Wang M, Liu B Heliyon. 2024; 10(16):e35836.

PMID: 39247380 PMC: 11379611. DOI: 10.1016/j.heliyon.2024.e35836.

References

Miazek-Zapala N, Slusarczyk A, Kusowska A, Zapala P, Kubacz M, Winiarska M . The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells. 2021; 10(6). PMC: 8232692. DOI: 10.3390/cells10061511. View

Chen X, Wood B . Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Rev. 2016; 31(2):63-75. DOI: 10.1016/j.blre.2016.09.006. View

Gao F, Ye Y, Gao Y, Huang H, Zhao Y . Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. Front Immunol. 2020; 11:2022. PMC: 7493622. DOI: 10.3389/fimmu.2020.02022. View

Willemsen L, Jol-van der Zijde C, Admiraal R, Putter H, Jansen-Hoogendijk A, Ostaijen-Ten Dam M . Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant. 2014; 21(3):473-82. DOI: 10.1016/j.bbmt.2014.11.674. View

Fei X, Zhang S, Gu J, Wang J . FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis. Cancer Med. 2022; 12(6):6877-6888. PMC: 10067110. DOI: 10.1002/cam4.5480. View

Kollman C, Spellman S, Zhang M, Hassebroek A, Anasetti C, Antin J . The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2015; 127(2):260-7. PMC: 4713163. DOI: 10.1182/blood-2015-08-663823. View

Sen R, Natarajan K, Bhullar J, Shukla S, Fang H, Cai L . The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012; 11(9):2033-44. PMC: 3683995. DOI: 10.1158/1535-7163.MCT-12-0302. View

Fathi A, Kim H, Soiffer R, Levis M, Li S, Kim A . Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022; 6(22):5857-5865. PMC: 9649991. DOI: 10.1182/bloodadvances.2022008632. View

Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y . Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance. Front Immunol. 2019; 10:93. PMC: 6367268. DOI: 10.3389/fimmu.2019.00093. View

10.

Liu Y, Ding L, Zhang B, Deng Z, Han Y, Wang S . Thrombopoietin enhances hematopoietic stem and progenitor cell homing by impeding matrix metalloproteinase 9 expression. Stem Cells Transl Med. 2020; 9(6):661-673. PMC: 7214666. DOI: 10.1002/sctm.19-0220. View

11.

Kebriaei P, Kline J, Stock W, Kasza K, Le Beau M, Larson R . Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005; 35(10):965-70. DOI: 10.1038/sj.bmt.1704938. View

12.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

13.

Gaman M, Cozma M, Dobrica E, Cretoiu S, Gaman A, Diaconu C . Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Life (Basel). 2021; 11(7). PMC: 8304270. DOI: 10.3390/life11070677. View

14.

Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J . Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016; 51(11):1431-1438. DOI: 10.1038/bmt.2016.167. View

15.

Adair J, Kubek S, Kiem H . Hematopoietic Stem Cell Approaches to Cancer. Hematol Oncol Clin North Am. 2017; 31(5):897-912. DOI: 10.1016/j.hoc.2017.06.012. View

16.

Nagler A, Labopin M, Dholaria B, Ciceri F, Fraccaroli A, Blaise D . Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Transplant Cell Ther. 2022; 28(11):773.e1-773.e8. DOI: 10.1016/j.jtct.2022.08.018. View

17.

Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J . Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015; 5:12993. PMC: 4585893. DOI: 10.1038/srep12993. View

18.

Zamai L, Del Zotto G, Buccella F, Gabrielli S, Canonico B, Artico M . Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy. Cells. 2020; 9(3). PMC: 7140651. DOI: 10.3390/cells9030753. View

19.

Elmariah H, Naqvi S, Kim J, Nishihori T, Mishra A, Perez L . Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021; 56(7):1683-1690. DOI: 10.1038/s41409-021-01219-8. View

20.

Toubert A, Glauzy S, Douay C, Clave E . Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens. 2012; 79(2):83-9. DOI: 10.1111/j.1399-0039.2011.01820.x. View